Jeronimo Espinosa
Country Medical Director for Central America & Caribbean at GSK | Buenos Aires, Buenos Aires Province, Argentina
Jeronimo Espinosa’s Email & Phone Number
VerifiedFree account · No credit card · 5 profiles/month
ContactOut Insights • AI Generated
Jeronimo Espinosa serves as the Country Medical Director for Central America and the Caribbean at GSK, directing respiratory and allergy therapeutic strategies across the region. He holds an MD and an MSc and completed his foundational training at King’s College London. Based in Buenos Aires, he leads regional medical affairs within the pharmaceutical industry to support clinical initiatives and healthcare standards throughout Latin America and the Caribbean.
BEST APPROACH TO REACH Jeronimo Espinosa
Contact him via a tailored LinkedIn message that highlights how your solution aligns with his current respiratory and allergy portfolio goals in the Central American and Caribbean markets to facilitate a targeted professional conversation.
Regional Scientific Director - Latin America (TMAC for Intellia Therapeutics) at Intellia Therapeutics, Inc. in January 2025 - Present
Country Medical Director for Central America & Caribbean at GSK in March 2023 - January 2025
Country Medical Director (Secondment) at GSK in April 2022 - March 2023
Respiratory and Allergy Medical Manager for Central America and Caribbean at GSK in March 2021 - March 2023
Respiratory Medical Manager and MSL Leader at GSK in June 2019 - March 2021
Respiratory Medical Manager at GSK in February 2018 - June 2019
Medical Manager Established Products at GSK in August 2017 - February 2018
Chevening Scholar at Chevening Awards in August 2016 - September 2017
MSc Drug Development Science at King's College London in September 2016 - August 2017
Medical Science Liaison (MSL) at Shire in August 2015 - September 2016
Out patient care in Internal Medicine clinic at CEMIC in June 2015 - August 2015
Internal Medicine Residency at CEMIC in June 2011 - June 2015
Medical Elective Rotation at Clinical Pharmacology Division at Johns Hopkins Hospital in October 2013 - December 2013
King's College London, Master of Science (MSc), October 2026
University of Buenos Aires, October 2026
Instituto Universitario CEMIC, October 2026
Intellia Therapeutics is a leading genome editing company whose mission is to develop potentially curative gene editing treatments that can positively transform the lives of people living with severe and life-threatening diseases. We are focused on the development of proprietary therapeutics using a recently developed biological tool known as the CRISPR/Cas9 system. The promise of the CRISPR/Cas9 system is the driving force behind the creation of Intellia. Our founders have a shared belief that the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. This technology offers the potential for us to develop curative therapeutic options for patients with chronic diseases by addressing the underlying cause of the disease. It can bring new hope and cures to people who now have nowhere to turn for help. Our combination of deep scientific expertise and clinical development experience, along with our leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Intellia has the right people, assets and ambitious vision needed to take full advantage of the CRISPR/Cas9 technology’s attributes – high potency, specificity, simplicity of use, broad applicability, and multifunctional programmability – and accelerate the advancement of curative products into the clinic. View our social media community guidelines at https://www.intelliatx.com/terms-and-conditions/ .
Discover more about GSK
Oligonucleotide Process Development
Associate Director at Intellia Therapeutics, Inc.
(October 2024 – Present)
RNA & Gene Editing Scientist | Nucleic Acid Therapeutics | Platform Development & Screening
Senior Associate Scientist at Intellia Therapeutics, Inc.
(July 2025 – Present)
NGS | Genomics | Biochemistry | Lab Automation
Senior Associate Scientist, Analytical Development (NGS) at Intellia Therapeutics, Inc.
(October 2023 – Present)
VP, Computational Sciences @ Intellia Therapeutics, Inc. | Ph.D in Biomedical Science
VP, Computational Sciences at Intellia Therapeutics, Inc.
(July 2025 – Present)
Intellia Therapeutics
Senior Associate Scientist at Intellia Therapeutics, Inc.
(March 2022 – Present)
Improving CRISPR using high-throughput lab automation
Associate Director, Automation at Intellia Therapeutics, Inc.
(January 2022 – Present)
What is Jeronimo Espinosa email address?
Email Jeronimo Espinosa at [email protected] and [email protected]. This email is the most updated Jeronimo Espinosa's email found in 2026.
How to contact Jeronimo Espinosa?
To contact Jeronimo Espinosa send an email to [email protected] or [email protected]. (updated on December 23, 2025)
What company does Jeronimo Espinosa work for?
Jeronimo Espinosa works for GSK.
What is Jeronimo Espinosa's role at GSK?
Jeronimo Espinosa is Country Medical Director for Central America & Caribbean
What industry does Jeronimo Espinosa work in?
Jeronimo Espinosa works in the Pharmaceuticals industry.
